Article
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 2135
under the following conditions: 50 mM Tris/HCl, pH 7.4,
154 mM NaCl, 5% DMSO, 0.1% PEG 8000 at 25 °C using
different concentrations of substrate and inhibitor. Ki values
(n g 3) were determined as described by Dixon.21
(9) Lafleur, K.; Huang, D.; Zhou, T.; Caflisch, A.; Nevado, C.
Structure-based optimization of potent and selective inhibitors of
the tyrosine kinase erythropoietin producinghuman hepatocellular
carcinoma receptor B4 (EphB4). J. Med. Chem. 2009, 52, 6433–
6446.
(10) Lumma, W. C., Jr.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.;
Sisko, J. T.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, B. J.; Vacca,
J. P. Design of novel, potent, noncovalent inhibitors of thrombin
with nonbasic P-1 substructures: rapid structure-activity studies
by solid-phase synthesis. J. Med. Chem. 1998, 41, 1011–1013.
(11) Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell,
S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.;
Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan,
M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.; Dancheck, K. B.;
Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Design and synthesis of
a series of potent and orally bioavailable noncovalent thrombin
inhibitors that utilize nonbasic groups in the P1 position. J. Med.
Chem. 1998, 41, 3210–3219.
Acknowledgment. We kindly acknowledge CSL Behring,
Marburg, Germany, for supplying us with generous amounts
of human thrombin from production of Beriplast. L.M.,
M.S., M.F., and D.G.H. contributed the design and synthesis
of the compounds, the modeling studies, and the MD simula-
tions, as well as collaborative interpretation of the data.
B.B., A.H., and G.K. contributed to the kinetic and the
collaborative interpretation of the data.
Supporting Information Available: Experimental details for
the synthesis of all the compounds. This material is available free
(12) Baum, B.; Mohamed, M.; Zayed, M.; Gerlach, C.; Heine, A.;
Hangauer, D.; Klebe, G. More than a simple lipophilic contact: a
detailed thermodynamic analysis of nonbasic residues in the s1
pocket of thrombin. J. Mol. Biol. 2009, 390, 56–69.
(13) Dullweber, F.; Stubbs, M. T.; Musil, D.; Sturzebecher, J.; Klebe,
G. Factorising ligand affinity: a combined thermodynamic and
crystallographic study of trypsin and thrombin inhibition. J. Mol.
Biol. 2001, 313, 593–614.
References
(1) Whitesides, G. M.; Krishnamurthy, V. M. Designing ligands to
bind proteins. Q. Rev. Biophys. 2005, 38, 385–395.
(2) Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.;
LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus,
S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff,
C. E.; Head, M. S. A critical assessment of docking programs and
scoring functions. J. Med. Chem. 2006, 49, 5912–5931.
(3) Hubbard, R. E. 3D structure and the drug-discovery process. Mol.
BioSyst. 2005, 1, 391–406.
(4) Talhout, R.; Villa, A.; Mark, A. E.; Engberts, J. B. Understanding
binding affinity: a combined isothermal titration calorimetry/
molecular dynamics study of the binding of a series of hydropho-
bically modified benzamidinium chloride inhibitors to trypsin.
J. Am. Chem. Soc. 2003, 125, 10570–10579.
(14) Stubbs, M. T.; Oschkinat, H.; Mayr, I.; Huber, R.; Angliker, H.;
Stone, S. R.; Bode, W. The interaction of thrombinwith fibrinogen.
A structural basis for its specificity. Eur. J. Biochem. 1992, 206,
187–195.
ꢀ
(15) Lila, C.; Gloanec, P.; Cadet, L.; Herve, Y.; Fournier, J.; Leborgne,
F.; Verbeuren, T. J.; De Nanteuil, G. Large-scale preparation of
protected 4-aminomethylbenzamidine. Application to the syn-
thesis of the thrombin inhibitor, melagatran. Synth. Commun.
1998, 28, 4419–4429.
(16) Vallone, B.; Miele, A. E.; Vecchini, P.; Chiancone, E.; Brunori, M.
Free energy of burying hydrophobic residues in the interface
between protein subunits. Proc. Natl. Acad. Sci. U.S.A. 1998, 95,
6103–6107.
(17) Bohm, H.-J., Schneider, G., Eds. Protein-Ligand Interactions:
From Molecular Recognition to Drug Design; Wiley-VCH: Wein-
heim, Germany, 2003; pp 3-20.
(18) Baum, B.; Muley, L.; Smolinski, M.; Heine, A.; Hangauer, D. G.;
Klebe, G. Unpublished results.
(19) Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular
dynamics. J. Mol. Graphics 1996, 14, 33–38.
(20) Sturzebecher, J.; Sturzebecher, U.; Vieweg, H.; Wagner, G.;
Hauptmann, J.; Markwardt, F. Synthetic inhibitors of bovine
factor Xa and thrombin comparison of their anticoagulant effi-
ciency. Thromb. Res. 1989, 54, 245–252.
(5) Nguyen, B.; Neidle, S.; Wilson, W. D. A role for water molecules in
DNA-ligand minor groove recognition. Acc. Chem. Res. 2009, 42,
11–21.
(6) Dill, K. A. Additivity principles in biochemistry. J. Biol. Chem.
1997, 272, 701–704.
(7) Williams, D. H.; Searle, M. S.; Mackay, J. P.; Gerhard, U.;
Maplestone, R. A. Toward an estimation of binding constants in
aqueous solution: studies of associations of vancomycin group
antibiotics. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1172–1178.
(8) Williams, D. H.; Stephens, E.; O’Brien, D. P.; Zhou, M. Under-
standing noncovalent interactions: ligand binding energy
and catalytic efficiency from ligand-induced reductions in motion
within receptors and enzymes. Angew. Chem., Int. Ed. 2004, 43,
6596–6616.
(21) Dixon, M. The graphical determination of Km and Ki. Biochem.
J. 1972, 129 (1), 197–202.